Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma

Endocrine-Related Cancer

Volumn 13, Issue 1, 2006, Pages 169-180

  Fung, K M ^a,c   Samara, E N S ^a   Wong, C ^a,c   Metwalli, A ^a   Krlin, R ^a   Bane, B ^a   Liu, C Z ^a   Yang, J T ^a   Pitha, J V ^a,c   Culkin, D J ^a,c   Kropp, B P ^a   Penning, T M ^b   Lin, Hsueh Kung ^a,c,d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 ENZYME; ANDROGEN RECEPTOR; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; ANDROSTERONE; CELL NUCLEUS RECEPTOR; MONOCLONAL ANTIBODY; PROSTAGLANDIN F; SYNTHETASE; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; HORMONE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; METAPLASIA; MOUSE; NONHUMAN; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

3-HYDROXYSTEROID DEHYDROGENASES; ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 33645987281     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01048     Document Type: Article

References (38)

1. Bishop-Bailey D & Wray J 2003 Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins and other Lipid Mediators 71 1-22.
2. 2. Cell Growth and Differentiation 11 49-61.
3. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K & Chang C 1992 Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. Journal of Urology 147 798-803.
4. Desmond JC, Mountford JC, Drayson MT, Walker EA, Hewison M, Ride JP, Luong QT, Hayden RE, Vanin EF & Bunce CM 2003 The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Research 63 505-512.
5. Dufort I, Soucy P, Labrie F & Luu-The V 1996 Molecular cloning of human type 3 3α-hydroxysteroid dehydrogenase that differs from 20α-hydroxysteroid dehydrogenase by seven amino acids. Biochemical and Biophysical Research Communications 228 474-479.
6. El-Alfy M, Luu-The V, Huang X-F, Berger L, Labrie F & Pelletier G 1999 Localization of type 5 17β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 140 1481-1491.
7. Fung KM, Lee VM & Trojanowski JQ 1995 Dynamics of cell proliferation and cell death during the emergence of primitive neuroectodermal tumors of the immature central nervous system in transgenic mice. American Journal of Pathology 146 1376-1387.
8. Heller A, Koch T, Schmeck J & van Ackern K 1998 Lipid mediators in inflammatory disorders. Drugs 55 487-496.
9. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S & Koeffler HP 2000 Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer. Cancer Research 60 5494-5498.
10. Isaacs JT, Furuya Y & Berges R 1994 The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Seminars in Cancer Biology 5 391-400.
11. Jacobi GH, Moore RJ & Wilson JD 1978 Studies on the mechanism of 3α-androstanediol-induced growth of the dog prostate. Endocrinology 102 1748-1755.
12. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM et al. 2005 Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Research 65 6189-6198.
13. Kirschenbaum A, Liu X, Yao S & Levine AC 2001 The role of cyclooxygenase-2 in prostate cancer. Urology 58 127-131.
14. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, El-Alfy M, Pelletier G & Belanger A 2000a Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. Journal of Molecular Endocrinology 25 1-16.
15. Labrie F, Luu-The V, Lin SX, Simard J & Labrie C 2000b Role of 17β-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends in Endocrinology and Metabolism 11 421-427.
16. Lang SH, Stark M, Collins A, Paul AB, Stower MJ & Maitland NJ 2001 Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth and Differentiation 12 631-640.
17. Leihy MW, Shaw G, Wilson JD & Renfree MB 2004 Penile development is initiated in the tammar wallaby pouch young during the period when 5α-androstane-3α,17β-diol is secreted by the testes. Endocrinology 145 3346-3352.
18. Lin H-K, Jez JM, Schlegel BP, Peehl DM, Pachter JA & Penning TM 1997 Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution. Molecular Endocrinology 11 1971-1984.
19. Lin H-K, Steckelbroeck S, Fung K-M, Jones AN & Penning TM 2004 Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69 795-801.
20. Mahendroo MS, Cala KM & Russell DW 1996 5α-reduced androgens play a key role in murine parturition. Molecular Endocrinology 10 380-392.
21. 2 11-ketoreductase activity. Journal of Biochemistry 124 940-946.
22. 2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. International Journal of Oncology 25 493-502.
23. Nunlist EH, Dozmorov I, Tang Y, Cowan R, Centola M & Lin H-K 2004 Partitioning of 5α-dihydrotestosterone and 5α-androstane-3α,17β-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation. Journal of Steroid Biochemistry and Molecular Biology 91 157-170.
24. Pelletier G, Luu-The V, Tetu B & Labrie F 1999 Immunocytochemical localization of type 5 17β-hydroxysteroid dehydrogenase in human reproductive tissues. Journal of Histochemistry and Cytochemistry 47 731-737.
25. Pelletier G, Luu-The V, El-Alfy M, Li S & Labrie F 2001 Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. Journal of Molecular Endocrinology 26 11-19.
26. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N & Ratnam K 2000 Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochemical Journal 351 67-77.
27. Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore M, Ratnam K & Palackal N 2001 Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). Molecular and Cellular Endocrinology 171 137-149.
28. Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR & Penning TM 2003 Human type 3 3α-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144 2922-2932.
29. Sabichi AL, Subbarayan V, Llansa N, Lippman SM & Menter DG 2004 Peroxisome proliferator-activated receptor-γ suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiology, Biomarkers and Prevention 13 1704-1709.
30. Schultz FM & Wilson JD 1974 Virilization of the Wolffian duct in the rat fetus by various androgens. Endocrinology 94 979-986.
31. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM & Menter DG 2004 Differential peroxisome proliferator-activated receptor-γ isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiology, Biomarkers and Prevention 13 1710-1716.
32. Varley CL, Stahlschmidt J, Smith B, Stower M & Southgate J 2004 Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. American Journal of Pathology 164 1789-1798.
33. Walsh PC & Wilson JD 1976 The induction of prostatic hypertrophy in the dog with androstanediol. Journal of Clinical Investigation 57 1093-1097.
34. Wilson JD, Auchus RJ, Leihy MW, Guryev OL, Estabrook RW, Osborn SM, Shaw G & Renfree MB 2003a 5α-androstane-3α,17β-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α,17α-diol-20-one as a key intermediate. Endocrinology 144 575-580.
35. Wilson JD, Leihy MW, Shaw G & Renfree MB 2003b Unsolved problems in male physiology: studies in a marsupial. Molecular and Cellular Endocrinology 211 33-36.
36. Yee LD, Guo Y, Bradbury J, Suster S, Clinton SK & Seewaldt VL 2003 The antiproliferative effects of PPARγ ligands in normal human mammary epithelial cells. Breast Cancer Research and Treatment 78 179-192.
37. Zang C, Liu H, Posch MG, Waechter M, Facklam M, Fenner MH, Ruthardt M, Possinger K, Phillip Koeffler H & Elstner E 2004 Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leukemia Research 28 387-397.
38. Zimmerman RA, Dozmorov I, Nunlist EH, Tang Y, Li X, Cowan R, Centola M, Frank MB, Culkin DJ & Lin H-K 2004 5α-Androstane-3α,17β-diol activates a pathway that resembles the epidermal growth factor responsive pathways in stimulating human prostate cancer LNCaP cell proliferation. Prostate Cancer and Prostatic Diseases 7 364-374.